3118 Stock Overview
Engages in marketing and distributing cell culture, immunology, and molecular biology products in Taiwan. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
My Notes
Capture your thoughts, links and company narrative
Level Biotechnology Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$32.40 |
| 52 Week High | NT$39.90 |
| 52 Week Low | NT$29.60 |
| Beta | 0.59 |
| 1 Month Change | 1.25% |
| 3 Month Change | 0.47% |
| 1 Year Change | 8.18% |
| 3 Year Change | 10.02% |
| 5 Year Change | 15.10% |
| Change since IPO | 149.05% |
Recent News & Updates
Recent updates
Some Investors May Be Worried About Level Biotechnology's (GTSM:3118) Returns On Capital
Apr 27
Calculating The Fair Value Of Level Biotechnology Inc. (GTSM:3118)
Mar 16Here's What You Should Know About Level Biotechnology Inc.'s (GTSM:3118) 3.6% Dividend Yield
Feb 14Does Level Biotechnology's (GTSM:3118) Returns On Capital Reflect Well On The Business?
Jan 24
Level Biotechnology Inc.'s (GTSM:3118) Stock Has Shown A Decent Performance: Have Financials A Role To Play?
Jan 03Calculating The Intrinsic Value Of Level Biotechnology Inc. (GTSM:3118)
Dec 16Here's Why We Think Level Biotechnology's (GTSM:3118) Statutory Earnings Might Be Conservative
Nov 28Shareholder Returns
| 3118 | TW Healthcare | TW Market | |
|---|---|---|---|
| 7D | 0% | 0% | 0% |
| 1Y | 8.2% | -11.8% | 28.6% |
Return vs Industry: 3118 exceeded the TW Healthcare industry which returned -11.8% over the past year.
Return vs Market: 3118 underperformed the TW Market which returned 28.6% over the past year.
Price Volatility
| 3118 volatility | |
|---|---|
| 3118 Average Weekly Movement | 1.4% |
| Healthcare Industry Average Movement | 3.6% |
| Market Average Movement | 4.4% |
| 10% most volatile stocks in TW Market | 7.8% |
| 10% least volatile stocks in TW Market | 2.1% |
Stable Share Price: 3118 has not had significant price volatility in the past 3 months compared to the TW market.
Volatility Over Time: 3118's weekly volatility (1%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1989 | 126 | n/a | www.level.com.tw |
Level Biotechnology Inc. engages in marketing and distributing cell culture, immunology, and molecular biology products in Taiwan. It also markets and distributes biomedical precision equipment. In addition, the company provides services in the areas of mammalian and genetic toxicology, pharmacology, biocompatibility, and model animal production.
Level Biotechnology Inc. Fundamentals Summary
| 3118 fundamental statistics | |
|---|---|
| Market cap | NT$1.05b |
| Earnings (TTM) | NT$65.45m |
| Revenue (TTM) | NT$716.09m |
16.1x
P/E Ratio1.5x
P/S RatioIs 3118 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 3118 income statement (TTM) | |
|---|---|
| Revenue | NT$716.09m |
| Cost of Revenue | NT$481.12m |
| Gross Profit | NT$234.97m |
| Other Expenses | NT$169.52m |
| Earnings | NT$65.45m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 2.02 |
| Gross Margin | 32.81% |
| Net Profit Margin | 9.14% |
| Debt/Equity Ratio | 0% |
How did 3118 perform over the long term?
See historical performance and comparisonDividends
5.2%
Current Dividend Yield84%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/30 00:03 |
| End of Day Share Price | 2025/01/22 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Level Biotechnology Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|